Patented Medicine Prices Review Board

Patented Medicine Prices Review Board

March 19, 2009 16:30 ET

The PMPRB Will Hold a Public Hearing Into the Price of Neulasta

OTTAWA, ONTARIO--(Marketwire - March 19, 2009) - The Patented Medicine Prices Review Board will hold a public hearing commencing on September 28, 2009, in the matter of Amgen Canada Inc. and the price of the patented medicine Neulasta. A pre-hearing conference will also be held on June 3.

The purpose of the hearing is to determine whether, under sections 83 and 85 of the Patent Act, Amgen is selling or has sold the medicine Neulasta in any market in Canada at a price that, in the Board's opinion, is or was excessive and if so, what order, if any, should be made.

Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with cancer receiving myelosuppressive chemotherapy.

Persons wishing to intervene in this proceeding are required to apply to the Board for leave to intervene on or before April 13, 2009. Such persons should contact the Secretary of the Board for further information on the procedure.

The Notice of Hearing in this matter and the Statement of Allegations of Board Staff are available on the PMPRB Web site under Regulatory; Hearings.

All requests for information should be addressed to the Secretary of the Board.

Contact Information

  • Patented Medicine Prices Review Board
    Sylvie Dupont
    Secretary
    613-954-8299 / Toll-free number: 1-877-861-2350
    613-952-7626 (FAX)
    sylvie.dupont@pmprb-cepmb.gc.ca